



Curriculum Vitae Europass



Curriculum Vitae Europass

Informazioni personali

Nome(i) / Cognome(i) **Bruno Fabris**

Indirizzo(i) **...**

Telefono(i) **...**

Fax **...**

E-mail **...**

Cellulare:

Cittadinanza **Italiana**

Data di nascita

Sesso **M**

Occupazione desiderata/Settore professionale

Facoltativo (v. istruzioni)

Esperienza professionale

Date Inziare con le informazioni più recenti ed elencare separatamente ciascun impiego pertinente ricoperto. Facoltativo (v. istruzioni)

Lavoro o posizione ricoperti **Direttore della Struttura Semplice di Endocrinologia**

Principali attività e responsabilità Attività di coordinamento, visite ambulatoriali, consulenze specialistiche

Nome e indirizzo del datore di lavoro Azienda Ospedaliero-Universitaria di Trieste

Tipo di attività o settore **Dirigenziale**

Date **1/11/1988 – 31/07/1989**

Lavoro o posizione ricoperti **Senior Research Fellow**

Principali attività e responsabilità Attività di ricerca

Nome e indirizzo del datore di lavoro Università di Melbourne (Australia)

Tipo di attività o settore **Medicina Interna**

Date **01/07/1986 a tutt'ora**

Lavoro o posizione ricoperti **Dirigente Medico di I livello**

Principali attività e responsabilità Assistenza e cura pazienti ricoverati

Nome e indirizzo del datore di lavoro Azienda Ospedaliero-Universitaria di Trieste

Tipo di attività o settore **Medicina Interna**

Date **15/07/1984 – 30/06/1986**

Lavoro o posizione ricoperti **Borsista Ospedaliero**

Principali attività e responsabilità Attività di supporto nell'assistenza e cura dei pazienti ricoverati

Nome e indirizzo del datore di lavoro	Azienda Ospedaliera di Trieste
Tipo di attività o settore	Medicina Interna
Date	13/10/1980 – 12/04/1981
Lavoro o posizione ricoperti	Assistente di Medicina Generale
Principali attività e responsabilità	Attività di supporto nell'assistenza e cura dei pazienti ricoverati
Nome e indirizzo del datore di lavoro	Azienda Ospedaliera di Trieste
Tipo di attività o settore	Medicina Interna
Istruzione e formazione	
Date	Novembre 2010
Titolo della qualifica rilasciata	Direttore della Scuola di Specializzazione in Medicina Interna
Principali tematiche/competenze professionali possedute	Direzione
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studio di Trieste
Date	2002
Titolo della qualifica rilasciata	Professore Associato Specialista Europeo dell'Ipertensione Arteriosa
Principali tematiche/competenze professionali possedute	Attività di consulenza e ambulatoriale
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Società Europea dell'Ipertensione Arteriosa
Date	1 novembre 2002
Titolo della qualifica rilasciata	Professore Associato
Principali tematiche/competenze professionali possedute	Attività didattica, di ricerca assistenziale in regime convenzionale
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studio di Trieste
Date	Maggio 1991
Titolo della qualifica rilasciata	Ricercatore Universitario
Principali tematiche/competenze professionali possedute	Attività di ricerca e assistenziale in regime convenzionale
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studio di Trieste
Date	10/11/1987
Titolo della qualifica rilasciata	Specialista in Endocrinologia
Principali tematiche/competenze professionali possedute	Attività ambulatoriale, di consulenza e di ricerca
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Verona
Date	19/03/1985
Titolo della qualifica rilasciata	Culture della materia di Patologia Speciale Medica e Metodologia Clinica
Principali tematiche/competenze professionali possedute	Attività tutoriale e partecipazione alle commissioni di esame
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Trieste
Date	09/11/1984
Titolo della qualifica rilasciata	Specialista in Nefrologia
Principali tematiche/competenze professionali possedute	Attività ambulatoriale, di consulenza e di ricerca

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione | Università degli Studi di Trieste

Date | 21/03/1980

Titolo della qualifica rilasciata | Laurea in Medicina e Chirurgia (110/110 e lode)

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione | Università degli Studi di Trieste

Date | 1972

Titolo della qualifica rilasciata | Maturità Scientifica

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione | Liceo Scientifico Michelangelo Buonarroti di Monfalcone (Gorizia)

Capacità e competenze personali

Madrelingua(e) | Italiana

Altra(e) lingua(e) | Inglese

Autovalutazione

Livello europeo (*)

Lingua

Lingua

Comprensione		Parlato		Scritto
Ascolto	Lettura	Interazione orale	Produzione orale	
Avanzato	Avanzato	Avanzato	Avanzato	Avanzato
Avanzato	Avanzato	Avanzato	Avanzato	Avanzato

(*) Quadro comune europeo di riferimento per le lingue

Capacità e competenze informatiche | Buona

Altre capacità e competenze | Descrivere tali competenze e indicare dove sono state acquisite. (facoltativo, v. istruzioni)

Patente | PATENTE DI GUIDA B Rilasciata il 30/07/71

Ulteriori informazioni | Inserire qui ogni altra informazione utile, ad esempio persone di riferimento, referenze, ecc. (facoltativo, v. istruzioni)

Allegati | Enumerare gli allegati al CV.
Allegato 1: Attività didattica, di ricerca ed elenco pubblicazioni

Firma | Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali (facoltativo)".

Trieste, 16/09/2022

ALLEGATO 1 (PUBBLICAZIONI)

E' autore di **139** pubblicazioni con **Impact Factor**

21 pubblicazioni censite ma **senza Impact Factor**

E' altresì autore di 245 contributi scientifici come Poster a Congressi Nazionali ed Internazionali (elenco non riportato)

Numero citazioni (Scopus): 5070

Numero citazioni (Google Scholar): 7189

H index (Scopus): 37

H index (Google Scholar): 43

1) Is the adrenal incidentaloma functionally active? An approach-to-the-patient-based review.

Bernardi S, Calabrò V, Cavallaro M, Lovriha S, Eramo R, **Fabris B**, de Manzini N, Dobrinja C

J Clin Med 2022 Jul 14;11(14):4064. Doi: 10.3390/jcm11144064.

2) A case report of PTH elevation due to immunoassay interference.

Calabrò V, Lovriha S, Zandonà L, Sirianni F, **Fabris B**, Bernardi S.

J Endocrinol Invest. 2022 Jul 18. Doi: 10.1007/s4061-022-01871-x.

3) Meta-analysis on the association between thyroid hormone disorders and arterial stiffness.

Bernardi S, Grillo A, Antonello RM, Cola MF, Dobrinja C, **Fabris B**, Giudici F

J Endocr Soc 2022 Feb 6;6(4):bvac016. DOI: 10.1210/jendso/bvac016.;

4) Discriminatory value of adiponectin to leptin ratio for COVID-19 pneumonia

Tonon F, Di Bella S, Giudici F, Zerbato V, Segat L, Koncan R, Misin A, Toffoli B, D'Agaro P, Luzzati R, **Fabris B**, Bernardi S

Int J Endocrinol 2022 Apr 26;2022:9908450.DOI: 10.1155/2022/9908450

5) Arterial stiffness in thyroid and parathyroid diseases: A review of clinical studies.

Grillo A, Barbato V, Antonello RM, Cola MF, Parati G, Salvi P, **Fabris B**, Bernardi S.

J Clin Med 2022 Jun 11(11):3146. DOI: 10.3390/jcm11113146.

6) Assessment of prasi changes of vascular size by automated edge tracking-state of the art and clinical perspectives.

Mesin L, Albani S, Policastro P, Pasquero P, Porta M, Melchiorri C, Leonardi G, Albera C, Scacciatella P, Pellicori P, Stolfo D, Grillo A, **Fabris B**, Bini R, Giannoni A, Pepe A, Ermini L, Sedone S, Sinagra G, Antonini-Canterin F, Roatta S

Front Cardiovasc Med 2022 Jan 21;8:775635. Doi: 10.3389/fcvm.2021.775635.

7) Children with short stature display reduced ACE2 expression in peripheral blood mononuclear cells

Tonon F, Tornese G, Giudici F, Nicolardi F, Toffoli B, Barbi E, **Fabris B**, Bernardi S

Front Endocrinol 2022 Jul 15;13:912064. Doi:10.3389/fendo.2022.912064.

8) Estimation of aortic stiffness with Bramwell-Hill equativo: a comparative analysis with carotid-femoral pulse wave velocity

Mesin L, Floris I, Policastro P, Albani S, Scacciatella P, Pugliese N, Masi S, Grillo A, **Fabris B**, Antonini-Canterin F

Bioengineering 2022 Jun 21;9(7):265. Doi:10.3390/bioengineering9070265.

9) Type 1 diabetes is associated with significant changes of ACE and ACE2 expression in peripheral blood mononuclear cells

tonon F, Candido R, Toffoli B, Tommasi E, Cortello T, **Fabris B**, Bernardi S

Nutr Metab Cardiovasc Dis. 2022 May;32(5):1275-1282. Doi: 10.1016/j.numecd.2022.01.029.

- 10) Validation of non invasive method to estimate subendocardial oxygen supply and demand balance.
Grillo A, Parati G, Salvi L, Scolise F, Ton I, Sorrapago A, Sorrapago G, De Censi L, Rovina M, **Fabris B**, Moretti F, Avolio A
J Hypertens 2022 (1June) Vol 40 Pages e234. DOI: 10.1097/01.hjh.0000837880.91713.d6

- 11) TRAIL/DR5 pathway promotes AKT phosphorylation skeletal muscle differentiation, and glucose uptake
Toffoli B, Tonon F, Tisato V, Zauli G, Secchiero P, **Fabris B**, Bernardi S
Cell Death Dis. 2021 Nov 16; 12(12):1089. Doi: 10.1038/s41419-021-04383-3.

- 12) Meta-analysis on the effect of mild primary hyperparathyroidism and parathyroidectomy upon arterial stiffness.
Bernardi S, Giudici F, Barbato V, Zanatta L, Grillo A, **Fabris B**
J Clin Endocrinol Metab 2021 May 13;106(6):1832-1843. Doi: 10.1210/clinem/dgab157.

- 13) Comparison between invasive and non invasive methods to estimate subendocardial oxygen supply and demand imbalance.
Salvi P, Baldi C, Scalise F, Grillo A, Salvi L, Tan I, De Censi L, Sorrapago A, Moretti F, Sorrapago G, Gao L, Rovina M, Simon G, **Fabris B**, Carretta R, Avolio AP, Parati G
J Am Heart Assoc 2021 Sep 7;10(17):e021207. Doi: 10.1161/JAHA.121.021207.

- 14) Current status and challenges of US-guided radiofrequency ablation of thyroid nodules in the long term: A systematic review
Bernardi S, Palermo A, Grasso RF, **Fabris B**, Stacul F, Cesareo R.
Cancers. 2021 Jun 1;13(11):2746. Doi:10.3390/cancers13112746.

- 15) Residual vital ratio predicts 5 years volume reduction and re treatment after radiofrequency ablation of benign thyroid nodules but not regrowth
Bernardi S, Giudici F, Colombin G, Cavallaro M, Stacul F, **Fabris B**.
Int J Hyperthermia 2021;38(1):111-113. Doi:10.1080/02656736.2021.1876931.

- 16) Initial ablation ratio predicts volume reduction and re treatment after 5 years from radiofrequency ablation of benign thyroid nodules
Bernardi S, Cavallaro M, Colombin G, Giudici F, Zuolo G, Zdjelar A, Dobrinja C, De Manzini N, Zanconati F, Cova MA, Stacul F, **Fabris B**.
Front Endocrinol. 2021 Feb 1;11:582550. Doi:10.3389/fendo.2020.582550.

- 17) The 2020 Italian society of arterial hypertension (SIIA) practical guidelines for the management of primary aldosteronism.
Rossi GP, Bisogni V, Bacca AV, Belfiore A, Cesari M, Concistrè A, Del Pinto R, **Fabris B**, Fallo F, Fava C, Ferri C, Giachetti G, Grassi G, Letizia C, Maccario M, Mallamaci F, Maiolino G, Manfredotto D, Minuz P, Monticone S, Morganti A, Muesan ML, Mulatero P, Negro A, Parati G, Pengo MF, Petramal L, Pizzolo F, Rizzoni D, Rositto G, Veglio F, Seccia TM
Int J Cardiol Hypertens 2020 Apr 15;5:100029. Doi:10.1016/j.ijchy.2020.100029.

- 18) Sex differences in proatherogenic cytokine levels.
Bernardi S, Toffoli B, Tonono F, Francica M, Campanolo E, Ferretti T, Comar S, Giudici F, Stenner E, **Fabris B**
Int J Mol Sci 2020 May 29;21(11):3861. Doi:10.3390/ijms21113861.

- 19) Radiofrequency ablation on autonomously functioning thyroid nodules: a critical appraisal and review of the literature.
Cesareo R, Palermo A, Pasqualini V, Manfrini S, Trimboli P, Stacul F, **Fabris B**, Bernardi S
Front Endocrinol 2020 May 22;11:317. doi: 10.3389/fendo.2020.00317.

- 20) Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2.
Manganotti P, Pesavento V, Buoite Stella A, Bonzi L, Campagnolo E, Bellavita G, **Fabris B**, Luzzati R.
J Neurovirol 2020, Aug 26(4); 605-606. DOI: 10.1007/s13365-020-00858-9.

21) TRAIL treatment prevents renal morphology changes and TGF- β -induced mesenchymal transition associated with diabetic nephropathy.

Toffoli B, Tonon F, Tisato V, Michelli A, Zauli G, Secchiero P, **Fabris B**, Bernardi S.

Clin Sci. 2020 Sep 18; 134(17):2337-2352. Doi:10.1042/CS20201004.

22) Mean arterial pressure estimated by brachial pulse wave analysis and comparison with currently used algorithms.

Grillo A, Salvi P, Furlanis G, Baldi C, Rovina M, Salvi L, Faini A, Bilo G, **Fabris B**, Carretta R, Benetos A, Parati G.

J Hypertens 2020 Nov; 38(11):2161-2168. Doi:10.1097/HJH.0000000000002564.

23) Relationship between aortic valve stenosis and the hemodynamic pattern in the renal circulation, and restoration of the flow wave profile after correction of the valvular defect.

Bardelli M, Cavressi M, Furlanis G, Pinamonti B, Leone M, Albani S, Korcova R, **Fabris B**, Sinagra G

J Int Med Res. 2020 Sep;48(9):30060520956907. Doi:10.1177/0300060520956907.

24) Impact of the Italian Society of anatomic pathology and diagnostic cytology classification of the thyroid nodules in the treatment of the indeterminate follicular lesions: five-year results at a single center.

Pastoricchio M, Cubisino A, Lanzaro A, Troian M, Zanconati F, Bernardi S, **Fabris B**, De Manzini N, Dobrinja C.

Int J Endocrinol 2020 Apr 14;2020:7325260. Doi:10.1155/2020/7325260.

25) A prospective study on the efficacy of patient stimulation in heart and lung auscultation.

Bernardi S, Giudici F, Leone MF, Zuolo G, Furlotti S, Carretta R, **Fabris B**.

BMC Med Educ 2019 Jul 23;19(1):275. Doi: 10.1186/s12909-019-1708-6

26) Unreliable Estimation of aortic pulse wave velocity provided by the mobil-o-graph algorithm-based system in Marfan syndrome

salvi P, Furlanis G, Grillo A, Pini A, Salvi L, Marelli S, Rovina M, Moretti F, Gaetano R, Pintassilgo I, Faini A, **Fabris B**, Carretta R, Parati G.

J Am Heart Assoc 2019 May 7;8(9):e04028. Doi: 10.1161/JAHA.118.011440

27) The complex interplay between lipids, immune system and interleukins in cardio-metabolic diseases

Bernardi S, Marcuzzi A, Piscianz E, Tommasini A, **Fabris B**.

Int J Mol Sci 2018 Dec 14;19(12):4058. Doi:10.3390/ijms19124058.

28) Usefulness of core needle biopsy for the diagnosis of thyroid Burkitt's lymphoma: a case report and review of the literature

Bernardin S, Michelli A, Bonazza D, Calabrò V, Zanconati F, Pozzato G, **Fabris B**.

BMC Endocr Disord 2018 Nov 19;18(1):86. Doi: 10.1186/s12902-018-0312-9.

29) Ambulatory blood pressure monitoring derived short term blood pressure variability in primary hyperparathyroidism.

Concistre A, Grillo A, Lo Torre G, Carretta R, **Fabris B**, Petramala L, Marinelli C, Rebellato A, Fallo F, Letizia C

Endocrine 2018 Apr;60(1):129-137. Doi: 10.1007/s12020-017-1362-x.

30) Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term.

Rossi GP, Maiolino G, Flego A, Belfiore A, Bernini G, **Fabris B**, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Muiesan ML, Mannelli M, Negro A, Palumbo G, Parenti G, Rossi E, Mantero F,; PAPY Study Investigators

Hypertension 2018 Apr;71(4):585-591. Doi:10.1161/HYPERTENSIONAHA.117.10596.

31) TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

Bernardi S, Toffoli B, Tisato V, Bossi F, Biffi S, Lorenzon A, Zauli G, Secchiero P, **Fabris B**.

Clin Sci 2018 Jan 5; 132(1):69-83. Doi: 10.1042/CS20171221.

32) Patient satisfaction after thyroid RFA versus surgery for benign thyroid nodules: a telephone survey.

Bernardi S, Dobrinja C, Carere A, Giudici F, Calabrò V, Zanconati F, De Manzini N, **Fabris B**, Stacul F

- 33) A case report of hyponatremia after surgery for Conn's adenoma.
Furlanis G, Bernardi S, Cavressi M, Zandonà L, Carretta R, **Fabris B**, Bardelli M
J Renin Angiotensin Aldosterone Syst 2017; 18(4):1470320317740240
- 34) Ambulatory blood pressure monitoring-derived short-term blood pressure variability in primary hyperaldosteronism
Concistrè A, Grillo A, La Torre G, Carretta R, **Fabris B**, Petramata L, Marinelli C, Rebellato A, Falo F, Letizia C.
Endocrine 2017 Jul 12. Doi:10.1007/s12020-017-1362-x
- 35) Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
Bernardi S, Toffoli B, Bossi F, Candido R, Stenner E, Carretta R, Barbone F, **Fabris B**.
BMC Nephrol 2017 Jul 6; 18(1):219. Doi:1186/s12882-017-0625-3
- 35) Association between thyroid hormones and TRAIL
Bernardi S, Bossi F, Toffoli B, Giudici F, Bramante A, Furlanis G, Stenner E, Secchiero P, Zauli G, Carretta R, **Fabris B**.
Clin Biochem 2017 May 25. Pii:S0009-9120(17)30249-7. Doi:1016/j.clinbiochem.2017.05.011
- 36) Quantitative value of aldosterone-renin ratio for detection of aldosterone-producing adenoma: The aldosterone-renin ratio for primary aldosteronism (AQUARR) Study
Maiolino G, Rossitto G, Bisogni V, Cesari M, Seccia TM, Plebani M, Rossi GP, PAPY Study Investigators
J Am Heart Assoc. 2017 May 21;6(5). Pii:e005574. Doi:10.1161/JAHA.117.005574
- 37) Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is anything more to say? A decade experience in a single-center
Dobrinja C, Troian M, Cipolat Mis T, Rebez G, Bernardi S, **Fabris B**, Piscopello L, Makovac P, Di Gregorio F, de Manzini N
Int J Surg 2017 May;41 Suppl 1:S40-S47. Doi: 10.1016/j.ijssu.2017.01.113
- 38) Partial thyroidectomy for papillary thyroid microcarcinoma: is completion total thyroidectomy indicated?
Dobrinja C, Pastoricchio M, Troian M, Da Canal F, Bernardi S, **Fabris B**, de Manzini N
Int J Surg 2017 May;41 Suppl 1:S34-S39. Doi:10.1016/j.ijssu.2017.02.012
- 39) Influence of carotid atherosclerotic plaques on pulse wave assessment with arterial tonometry
Grillo A, Simon G, Salvi P, Rovina M, Baldi C, Prearo I, Bernardi S, **Fabris B**, Faini A, Parati G, Bardelli M, Carretta R
J Hypertens 2017 Aug;35(8):1609-1617. Doi:1097/HJH.0000000000001366
- 40) Ambulatory arterial stiffness indexes in Cushing's syndrome
Battocchio M, Rebellato A, Grillo A, Dassie F, Maffei P, Bernardi S, **Fabris B**, Carretta R, Fallo F.
Horm Metab Res 2017 Mar;49(3):214-220. Doi: 10.1055/s-0043-100385
- 41) Dyslipidemia and diabetes increase the OPG/TRAIL ratio in the cardiovascular system
Toffoli B, **Fabris B**, Bartelloni G, Bossi F, Bernardi S
Mediators Inflamm. 2016; 2016:6529728. Doi:1155/2016/6529728
- 42) 12-month efficacy of a single radiofrequency ablation on autonomously functioning thyroid nodules.
Bernardi S, Stacul F, Michelli A, Giudici F, Zuolo G, de Manzini N, Dobrinja C, Zanconati F, **Fabris B**.
Endocrine 2017; 57(3):402-408
- 43) Update on RAAS modulation for the treatment of diabetic cardiovascular disease.
Bernardi S, Michelli A, Zuolo G, Candido R, **Fabris B**.
J Diabetes Res 2016; 2016:8917578. Doi: 10.1155/2016/8917578
- 44) A case report of malignant hypertension in a young woman.

Michelli A, Bernardi S, Grillo A, Panizon E, Rovina M, Bardelli M, Carretta R, **Fabris B**.
BMC Nephrol 2016;17(1):65. Doi: 10.1186/s12882-016-0291-x

45) Roles and clinical applications of OPG and TRAIL as biomarkers in cardiovascular disease.
Bernardi S, Bossi F, Toffoli B, **Fabris B**.
Biomed Res Int 2016;2016: 1752854. Doi: 10.1155/2016/1752854

46) Radiofrequency ablation for benign thyroid nodules.
Bernardi S, Stacul F, Zecchin M, Dobrinja C, Zanconati F, **Fabris B**.
J Endocrinol Invest 2016;39:1003-13

47) Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome. Dobrinja C, Makovac P, Pastoricchio M, Cipolat Mis T, Bernardi S, **Fabris B**, Piscopello L, de Manzini N.
Int J Surg 2016; Suppl 1:S70-4

48) Angiotensin 1-7 significantly reduces diabetes-induced leukocyte recruitment both in vivo and in vitro.
Bossi F, Bernardi S, De Nardo D, Bramante A, Candido R, Carretta R, Fischetti F, **Fabris B**.
Atherosclerosis 2016; 244:121-30

49) Full-thickness skin burn caused by radiofrequency ablation of a benign thyroid nodule.
Bernardi S, Lanzilotti V, Papa G, Panizzo N, Dobrinja C, **Fabris B**, Stacul F.
Thyroid 2016;26:183-4

50) Aldosterone effects on glomerular structure and function.
Bernardi S, Toffoli B, Zennaro C, Bossi F, Losurdo P, Michelli A, Carretta R, Mulatero P, Fallo F, Veglio F, **Fabris B**.
J Renin Angiotensin Aldosterone Syst 2015;16:730-8

51) Surgical and pathological changes after radiofrequency ablation of thyroid nodules.
Dobrinja C, Bernardi S, **Fabris B**, Eramo R, Makovac P, Bazzocchi G, Piscopello L, Barro E, de Manzini N, Bonazza D, Pinamonti M, Zanconati F, Stacul F.
Int J Endocrinol 2015; 2015:576576. Doi: 10.1155/2015/576576

52) Ambulatory blood pressure monitoring-derived short-term blood pressure variability in primary aldosteronism.
Grillo A, Bernardi S, Rebellato A, **Fabris B**, Bardelli M, Burrello J, Rabbia F, Veglio F, Fallo F, Carretta R.
J Clin Hypertens 2015;17:603-8

53) Baroreflex sensitivity and central hemodynamics after omega-3 polyunsaturated fatty acids supplementation in an animal model of menopause.
Losurdo P, Grillo A, Panizon E, Zanetti M, Bardelli M, Biolo G, **Fabris B**, Carretta R.
Vascu Pharmacol 2015;71:65-9

54) Hypovitaminosis D and organ damage in patients with arterial hypertension: a multicenter double blind randomised controlled trial of cholecalciferol supplementation (HYPODD): study design, clinical procedures and treatment protocol.
Rendina D, Ippolito R, D'Elia L, Giacchetti G, Lonati C, Gianfrancesco F, Fallo F, Rebellato A, Ruggiero C, Rubattu S, Volpe M, Gennari L, Merlotti D, Isaia GC, D'Amelio P, Spertino E, **Fabris B**, Sechi LA, Catena C, Maresca AM, Gessi V, Dalbeni A, Strazzullo P.
High Blood Press Cardiovasc Prev 2015;22:135-42

55) TRAIL modulates the immune system and protects against the development of diabetes.
Bossi F, Bernardi S, Zauli G, Secchiero P, **Fabris B**.
J Immunol Res 2015;2015:680749. Doi: 10.1155/2015/680749

56) ACE2 deficiency shifts Energy metabolism towards glucose utilization.

- Bernardi S, Tikellis C, Candido R, Tsorotes D, Pickering RJ, Bossi F, Carretta R, **Fabris B**, Cooper ME, Thomas MC. *Metabolism* 2015;64:406-15
- 57) Cross-sex hormone therapy for gender dysphoria.
Fabris B, Bernardi S, Trombetta C.
J Endocrinol Invest 2015;38:269-82
- 58) Radifrequency ablation compared to surgery for the treatment of benign thyroid nodules.
 Bernardi S, Dobrinja C, **Fabris B**, Bazzocchi G, Sabato N, Ulcigrai V, Giacca M, Barro E, De Manzini N, Stacul F.
Int J Endocrinol 2014;2014:934595. Doi. 10.1155/2014/934595
- 59) Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes.
 Bernardi S, **Fabris B**, Thomas M, Toffoli B, Tikellis C, Candido R, Catena C, Mulatero P, Barbone F, Radillo O, Zauli G, Secchiero P.
Mol Cell Endocrinol 2014;394:13-20
- 60) Ambulatory blood pressure monitoring-derived short-term blood pressure variability is increased in Cushing's syndrome.
 Rebellato A, Grillo A, Dassie F, Sonino N, Maffei P, Martini C, Paoletta A, **Fabris B**, Carretta R, Fallo F.
Endocrine 2014;47:557-63
- 61) Supplementation of omega-3 polyunsaturated fatty acids prevents increase in arterial stiffness after experimental menopause.
 Losurdo P, Grillo A, Panizon E, Gortan Cappellari G, **Fabris B**, Bardelli M, Biolo G, Zanetti M, Carretta R.
J Cardiovasc Pharmacol Ther. 2014; 19(1):114-20
- 62) Treatment with n-3 polyunsaturated fatty acids reverses endothelial dysfunction and oxidative stress in experimental menopause.
 Gortan Cappellari G, Losurdo P, Mazzucco S, Panizon E, Jevnicar M, Macaluso L, **Fabris B**, Barazzoni R, Biolo G, Carretta R, Zanetti M.
J Nutr Biochem 2013; 24(1):371-9
- 63) Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension.
 Catena C, Bernardi S, Sabato N, Grillo A, Ermani M, Sechi LA, **Fabris B**, Carretta R, Fallo F.
Nutr Metab Cardiovasc Dis 2013;23(4):389-93
- 64) TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases.
 Bernardi S, Milani D, **Fabris B**, Secchiero P, Zauli G.
Curr Drug Targets 2012;13(9):1215-21
- 65) TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high- fat-fed mice reducing adiposity and systemic inflammation.
 Bernardi S, Zauli G, Tikellis C, Candido R, **Fabris B**, Secchiero P, Cooper ME, Thomas MC.
Cin Sci 2012; 123(9): 547-55
- 66) Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin- (1-7)
 Bernardi S, Burns WC, Toffoli B, Pickering R, Sakoda M, Tsorotes D, Grixti E, Velkoska E, Burrell LM, Johnston C, Thomas MC, **Fabris B**, Tikellis C.
Clin Sci 2012; 123(1): 29-37
- 67) Ambulatory arterial stiffness indexes in acromegaly. Dassie F, Grillo A, Carretta R, **Fabris B**, Macaluso L, Bardelli M, Martini C, Paoletta A, Vettor R, Siculo N, Fallo F, Maffei P.
Eur J Endocrinol 2012; 166(2): 199-205

- 68) Aldosterone does not modify gene expression in human endothelial cells.
Verhovez A, Williams TA, Morello F, Monticone S, Brizzi MF, Dentelli P, Fallo F, **Fabris B**, Amenta F, Gomez-Sanchez C, Veglio F, Mulatero P.
Horm Metab Res 2012; 44(3):234-8
- 69) Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma.
Bernardi S, Zennaro C, Palmisano S, Velkoska E, Sabato N, N, Toffoli B, Giacomel G, Buri L, Zanconati F, Bellini G, Burrell LM, De Manzini N, **Fabris B**.
J Renin Angiotensin Aldosterone Syst 2012; 13(1): 202-9
- 70) High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage.
Bernardi S, Toffoli B, Zennaro C, Tikellis C, Monticone S, Losurdo P, Bellini G, Thomas MC, Fallo F, Veglio F, Johnston CI, **Fabris B**. Nephrol Dial Transplant 2012; 27(5): 1793-800
- 71) A pheochromocytoma with high adrenocorticotrophic hormone and a silent lung nodule.
Bernardi S, Grimaldi F, Finato N, De Marchi S, Proclamer A, Sabato N, Bertolotto M, **Fabris B**.
Am J Med Sci 2011; 342(5): 429-32
- 72) Osteoprotegerin promotes vascular fibrosis via a TGF- β 1 autocrine loop.
Toffoli B, Pickering RJ, Tsorotes D, Wang B, Bernardi S, Kantharidis P, **Fabris B**, Zauli G, Secchiero P, Thomas MC.
Atherosclerosis 2011; 218(1): 61-8
- 73) Innate immunity, through late complement components activation, contributes to the development of early vascular inflammation and morphologic alterations in experimental diabetes.
Fischetti F, Candido R, Toffoli B, Durigutto P, Bernardi S, Carretta R, Tedesco F, **Fabris B**.
Atherosclerosis 2011; 216(1): 83-9
- 74) TRAIL shows potential cardioprotective activity.
Toffoli B, Bernardi S, Candido R, Zacchigna S, **Fabris B**, Secchiero P.
Invest New Drugs 2012; 30(3): 1257-1260
- 75) Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin- angiotensin system.
Fabris B, Candido R, Bortoletto M, Toffoli B, Bernardi S, Stebel M, Bardelli M, Zentilin L, Giacca M, Carretta R.
J Hypertens 2011; 29(2):273-81
- 76) Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets.
Toffoli B, Bernardi S, Candido R, Sabato N, Carretta R, Corallini F, Secchiero P, Zauli G, **Fabris B**.
Mol Cell Endocrinol 2011; 331(1):136-42
- 77) Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure.
Bernardi S, Candido R, Toffoli B, Carretta R, **Fabris B**.
Nephrol Dial Transplant 2011; 26(3):832-838
- 78) The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnostic aldosterone-producing adenoma. Rossi GP, Barisa M, Belfiore A, Desideri G, Ferri C, Letizia C, Maccario M, Morganti A, Palumbo G, Patalano A, Roman E, Seccia TM, Pessina AC, Mantero F; PAPY study Investigators.
J Hypertens 2010; 28(9): 1892-9
- 79) Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes.
Zauli G, Toffoli B, di Iasio MG, Celeghini C, **Fabris B**, Secchiero P.
Diabetes 2010; 59(5):1261-5

- 80) Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism.
Rossi GP, Seccia TM, Palumbo G, Belfiore A, Bernini G, Caridi G, Desideri G, **Fabris B**, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Patalano A, Rizzoni D, Rossi E, Pessina AC, Mantero F; Primary Aldosteronism in the Prevalence of Hypertension (PAPY) Study Investigators.
Hypertension 2010; 55(1):83-9
- 81) Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study.
Fallo F, Dalla Pozza A, Tecchio M, Tona F, Sonino N, Ermani M, Catena C, Bertello C, Mulatero P, Sabato N, **Fabris B**, Sechi LA.
Am J Hypertens 2010; 23(1):2-5
- 82) Human full-length osteoprotegerin induces the proliferation of rodent vascular smoothmuscle cells both in vitro and in vivo.
Candido R, Toffoli B, Corallini F, Bernardi S, Zella D, Voltan R, Grill V, Celeghini C, **Fabris B**.
J Vasc Res 2010; 47(3):252-61
- 83) Hypertension and diabetes: emphasis on the renin-angiotensin system in atherosclerosis.
R. Candido, S. Bernardi, **B. Fabris**.
Current Hypertension Reviews 2009; 19(9): 646-53
- 84) Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension.
Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G, Ermani M, Catena C, Soardo G, Di Piazza L, Bernardi S, Bertolotto M, Pinamonti B, **Fabris B**, Sechi LA.
Nutr Metab Cardiovas Dis 2009; 19(9):646-53
- 85) Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients.
Fallo F, Dalla Pozza A, Sonino N, Federspil G, Ermani M, Baroselli S, Catena C, Soardo G, Carretta R, Belgrado D, **Fabris B**, Sechi LA.
J Hypertension 2008; 26(11):2191-7
- 86) Orally administered microencapsulated lysozyme down regulates serum AGE and reduces the severity of early-stage diabetic nephropathy.
Cocchietto M, Zorzin L, Toffoli B, Candido R, **Fabris B**, Stebel M, Sava.
Diabetes Metab 2008; 34(6 Pt 1):587-94
- 87) Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients.
Rossi GP, Belfiore A, Bernini G, **Fabris B**, Caridi G, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Palumbo G, Palatano A, Rizzoni D, Rossi E, Pessina AC, Mantero F; Primary Aldosteronism Prevalence in hYpertension Study Investigators.
J Clin Endocrinol Metab 2008; 93(7): 2566-71
- 88) Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma.
Rossi GP, Belfiore A, Bernini G, Desideri G, **Fabris B**, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, D, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F; Primary Aldosteronism Prevalence in Italy Study Investigators.
Hypertension 2007; 50(2):424-31
- 89) Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma.
Rossi GP, Belfiore A, Bernini G, Desideri G, **Fabris B**, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemuro D, Palumbo G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero F; PAPY Study Investigators.

J Hypertens 2007 25(7):1433-42

90) Dose- and time-dependent apoptotic effects by angiotensin II infusion on left ventricular cardiomyocytes.

Fabris B, Candido R, Bortoletto M, Zentilin L, Sandri M, Fior F, Toffoli B, Stebel M, Bardelli M, Belgrado D, Giacca M, Carretta R.

J Hypertens. 2007; 25(7):1481-90

91) Renal damage in primary aldosteronism: results of the PAPY Study.

Rossi GP, Bernini G, Desideri G, **Fabris B**, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F; PAPY Study Participants.

Hypertension. 2006;48(2):232-8.

92) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice.

Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, **Fabris B**, Giacca M, Zauli G.

Circulation. 2006;114(14):1522-30.

93) An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.

Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, **Fabris B**, Celeghini C, Capitani S, Zauli G.

Am J Pathol. 2006;169(6):2236-44.

94) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.

Rossi GP, Bernini G, Caliumi C, Desideri G, **Fabris B**, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Matterello MJ, Moretti A, Palumbo G, Parenti G, Porter E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators.

J Am Coll Cardiol. 2006;48(11):2293-300.

95) Genetic polymorphisms of the renin-angiotensin-aldosterone system and renal insufficiency in essential hypertension.

Fabris B, Bortoletto M, Candido R, Barbone F, Cattin MR, Calci M, Scanferla F, Tizzoni L, Giacca M, Carretta R.

J Hypertens. 2005;23(2):309-16.

96) Glomerular permeability defect in hypertension is dependent on renin angiotensin system activation.

Candido R, Carraro M, Fior F, Artero ML, Zennaro C, Burrell LM, Davis BJ, Cattin MR, Bardelli M, Faccini L, Carretta R, **Fabris B**.

Am J Hypertens. 2005;18(6):844-50.

97) Large-artery hemodynamics after acute alcohol administration in young, healthy volunteers.

Fazio M, Bardelli M, **Fabris B**, Macaluso L, Fiammengio F, Vran F, Bossi M, Candido R, Gerloni R, Carretta R.

Angiology. 2004;55(2):139-45.

98) Genetic polymorphism of the renin-angiotensin-aldosterone system and arterial hypertension in the Italian population: the GENIPER Project.

Castellano M, Glorioso N, Cusi D, Sarzani R, **Fabris B**, Opocher G, Zoccali C, Golin R, Veglio F, Volpe M, Mantero F, Fallo F, Rossi GP, Barlassina C, Tizzoni L, Filigheddu F, Giacchè M, Rossi F; Molecular Genetic Study Group of the Italian Society of Hypertension.

J. Hypertens 2003;21(10):1853-60

89) Treatment for diabetic nephropathy - a review of the recent patent literature.

Candido R, **Fabris B**, Cooper ME.

I Drugs. 2002 Mar;5(3):237-65.

100) Modulation of incipient glomerular lesions in experimental diabetic nephropathy by hypotensive and subhypotensive

dosages of an ACE inhibitor.

Fabris B, Candido R, Carraro M, Fior F, Artero M, Zennaro C, Cattin MR, Fiorotto A, Bortoletto M, Millevoi C, Bardelli M, Faccini L, Carretta R.

Diabetes 2001; 50: 2619-24

101) Mechanics of the carotid artery wall and baroreflex sensitivity after acute ethanol administration in young healthy volunteers

Fazio M, Bordelli M, Macaluso L, Fiammengo F, Mattei PL, Bossi M, **Fabris B**, Fischetti F, Pascasio L, Candido R, Carretta R.

Clin Science 2001; 101: 253-260

102) Haemoconcentration, shear-stress increase and carotid artery diameter regulation after furosemide administration in older hypertensives. Fazio M, Bardelli M, Cominotto F, Fiammengo F, **Fabris B**, Fischetti F, Candido R, Pascasio L, Lapasin R, Carretta R.

Exp Gerontol 2001; 36: 571-581

103) Effects of prolonged high-altitude exposure on peripheral adrenergic receptors in young healthy volunteers.

Fischetti F, **Fabris B**, Zaccaria M, Biagi A, Calci M, Candido R, Bortoletto M, Carretta R.

Eur J Appl Physiol 2000; 82(5-6): 439-445.

104) Albumin permeability in isolated glomeruli in incipient experimental diabetes mellitus.

Carraro M, Mancini W, Artero M, Zennaro C, Faccini L, Candido R, Armini L, Calci M, Carretta R, **Fabris B**.

Diabetologia 2000; 43: 235-241

105) Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin convertine enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.

Fabris B, Candido R, Armini L, Fischetti F, Calci M, Bardelli M, Fazio M, Campanacci L, Carretta R.

J Hypertens. 1999; 17: 1925-1931.

106) Baroreceptor-heart rate reflex sensitivity enhancement after urinary bladder distension in essential hypertensives.

Bardelli M, Siracusano S, Cominotto F, Fazio M, Ussi D, **Fabris B**, de Giorgi G, Vigliercio G, Fischetti F, Carretta R.

Urol Res 1999; 27: 153-156

107) Systemic and regional haemodynamic effects of aortofemoral angiography.

Bardelli M, Fazio M, Cominotto F, Pozzi Mucelli F, Stacul F, **Fabris B**, Fischetti F, Ricci C, Carretta R.

Br J Radiol 2000; 73: 588-594

108) Regional and systemic haemodynamic response to aortography in hypertensives.

Bardelli M, Carretta R, Fazio M, Mucelli F, Stacul F, **Fabris B**, Fischetti F, Candido R, Campanacci L.

J Hypertens. 1999; 17: 1971-1976.

109) Relationship between mechanical properties of the carotid artery wall and baroreflex function in acutely treated hypertensive patients.

Carretta R, Bardelli M, Cominotto F, Ussi D, Fazio M, **Fabris B**, Fischetti F, Campanacci L.

J. Hypertens. 1996; 14 (9): 1105-1110

110) Contribution of systemic blood pressure to myocardial remodeling in uremic rats.

Fabris B, Carretta R, Fischetti F, Candido R, Calci M, Castellano M, Bardelli M, Campanacci L.

Hypertension 1995; 26: 321-326

111) Conflicting results on peripheral adrenoceptor function in hypotension of hemodialyzed patients.

Fabris B, Carretta R, Fischetti F.

Nephron 1994; 68(2): 270

- 112) Cardiac and nephroprotective effects of angiotensin converting enzyme inhibitor treatment in the renal ablation model.
Fabris B, Fischetti F, Carretta R, Narducci P, Piccinini C, Calci M, Biagi A, Candido R, Bardelli M, Campanacci L.
J. Hypertens. 1993; 11(suppl5): S344-S345
- 113) Ace inhibition in renal disease: risks and benefits.
Campanacci L, **Fabris B**, Fischetti F, Bardelli M, Vran F, Carretta R.
Clin Exper Hypert 1993; 15 (suppl1): 173-186
- 114) The cardiac renin-angiotensin system in heart failure.
Johnston CI, **Fabris B**, Yoshida K.
Am. Heart J. 1993; 126: 756-760
- 115) Intrarenal renin-angiotensin system in renal physiology and pathophysiology.
Johnston CI, **Fabris B**, Jandeleit K.
Kidney Int. 1993; 44(suppl. 42): S59-S63
- 116) An ultrasonographic method to measure the sensitivity of the baroreflex in clinical practice: application to pharmacological studies.
Carretta R, Bardelli M, Bulli G, **Fabris B**, Fischetti F, Vran F, Rizzini P, D'Onofrio V, Bamfi F, Campanacci L.
J. Hypertens. 1991; 9(Suppl 3): S33-S36
- 117) Peripheral adrenoceptors in hypotension of hemodialyzed uremic patients.
Carretta R, **Fabris B**, Fischetti F, Bardelli M, Muiesan S, Vran V, Vasile A, Campanacci L.
Nephron 1992; 62: 429-433
- 118) Salt blocks the renal benefits of ramipril in diabetic hypertensive rats.
Fabris B, Jackson B, Johnston CI.
Hypertension 1991; 17: 497-503
- 119) Changes in cardiac angiotensin converting enzyme after myocardial infarction and hypertrophy in rats.
Johnston CI, Mooser V, Sun Y, **Fabris B**.
Clin. Exp. Pharmacol. and Physiol. 1991; 18: 107- 110
- 120) Localization of angiotensin converting enzyme in rat heart.
Yamada H, **Fabris B**, Allen AM, Jackson B, Johnston CI, Mendelsohn FAO.
Cir. Res. 1991; 68 (1): 141-149
- 121) Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats.
Fabris B, Jamada H, Cubela R, Jackson B, Mendelsohn FAO, Johnston CI.
Br. J. Pharmacol. 1990; 100 (3): 651-655
- 122) Increased cardiac angiotensin converting enzyme in rats with chronic heart failure.
Fabris B, Jackson B, Kohzuki M, Perich R, Johnston CI.
Clin. Exp. Pharmacol. and Physiol. 1990; 17: 309-314
- 123) High salt diet ameliorates effects of angiotensin converting enzyme inhibition in spontaneously hypertensive streptozotocin diabetic rats.
Jackson B, **Fabris B**, Paxton D, Franze L, Johnston CI.
Clin and Exp. Pharmacol. and Physiol. 1990; 17: 229-234
- 124) Inhibition of angiotensin converting enzyme (ACE) in plasma and tissue.
Fabris B, Chen BZ, Pupic V, Perich R, Johnston CI.

J. Cardiovasc. Pharmacol. 1990; 15 (Suppl 2): S6-S13

125) Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists. Johnston CI, Hodsman PG, Kohzuki M, Casley DJ, **Fabris B**, Phillips PA. Am. J. Med. 1989; 87 (suppl 6B): 24S-28S

126) Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. Johnston CI, **Fabris B**, Yamada H, Mendelsohn FAO, Cubela R, Sivell D, Jackson B. J. Hypertens. 1989; 7 (Suppl 5): S11-S16

127) Angiotensin converting enzyme in the rat heart: studies of its inhibition in vitro and ex vivo. **Fabris B**, Jackson B, Cubela R, Mendelsohn FAO, Johnston CI. Clin. and Exp. Pharm. and Physiol. 1989; 16: 309-313

128) Reduction of blood pressure in obese hyperinsulinaemic hypertensive patients during somatostatin infusion. Carretta R, **Fabris B**, Fischetti F, Costantini M, De Biasi F, Muiesan S, Bardelli M, Vran F, Campanacci L. J. Hypertens. 1989; 7 (Suppl 6): S196-S197

129) Regional haemodynamic effect of slow release nicardipine in elderly patients with hypertension: evaluation by a new ultrasound technique. Carretta R, Bardelli M, Muiesan S, Vran F, **Fabris B**, Fischetti F, Campanacci L. Am. Heart J. 1989; 117 (1): 229-235

130) Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors. Johnston CI, Mendelsohn FAO, Cubela RB, Jackson B, Kohzuki M, **Fabris B**. J. Hypertens. 1988; 6 (Suppl 3): S17-S22

131) Arterial compliance and baroreceptor sensitivity after chronic treatment with indapamide. Carretta R, **Fabris B**, Bardelli M, Muiesan S, Fischetti F, Vran F, Bianchetti A, Campanacci L. J. Hum Hypertens. 1988; 2: 171-5

132) Acute effects of intravenous infusion of alcohol on baroreceptor sensitivity in essential hypertension. Carretta R, **Fabris B**, Bardelli M, Muiesan S, Fischetti F, Cesanelli R, Pizzolito A, Bianchetti A, Campanacci L. Cardiovasc. Res. 1988; 22: 226-230

133) Platelet alpha-2 adrenoceptor modifications induced by long-term treatment with indapamide in essential hypertension. Carretta R, **Fabris B**, Fischetti F, Muiesan S, Bardelli M, Melchior C, Cesanelli R, Pizzolito A, Giraldi T, Lo Greco P, Campanacci L. Am. J. Med. 1988; 84(Suppl 1B): 31-35

134) Haemodynamic effects of intravenous infusion of alcohol in essential hypertension. Carretta R, **Fabris B**, Bardelli M, Fischetti F, Muiesan S, Vran F, Bellini G, Campanacci L. J. Hypertens. 1987; 5 (Suppl. 5): S505-S507

135) Antihypertensive activity of arylidenaminoguanidine derivatives. Mamolo MG, Vio L, **Fabris B**, Fischetti F, Carretta R, Giraldi T. Il Farmaco Ed. Sci. 1986; 41(11): 873-880

136) Effects of cold on sodium and potassium excretion in young men genetically predisposed to hypertension. Carretta R, **Fabris B**, Tonutti L, Tence A, Bellini G, Battilana G, Cociancich L, Cian F, Gaspari T, Campanacci L. J. Hypertens. 1983; 1 (suppl. 2): 156-158

137) Antihypertensive effects and kidney function in hypertensive patients treated with atenolol and oxprenolol.

Bellini G, Battilana G, Carretta R, **Fabris B**, Puppis E, Rigoni A, Faccini L, Campanacci L.
Drugs 1983; 25(S2): 253-255

138) Effect of indapamide on the baroreceptor reflex in essential hypertension.
Carretta R, **Fabris B**, Tonutti L, Bellini G, Battilana G, Bianchetti, Campanacci L.
Eur. J. Clin. Pharmacol. 1983; 24(5):579-583

139) Baroreflex function after therapy withdrawal in patients with essential hypertension.
Carretta R, **Fabris B**, Bellini G, Tonutti L, Battilana G, Bianchetti A, Campanacci L.
Clin. Sci. 1983; 64: 259-263